Natural killer cells as a promising therapeutic target for cancer immunotherapy

Area of Science:

• Immunology
• Cancer Biology
• Cellular Therapeutics

Background:

• Natural killer (NK) cells are innate lymphoid cells critical for early cancer surveillance.
• NK cell dysfunction is linked to poor cancer prognosis, highlighting their therapeutic potential.
• NK cells offer MHC-unrestricted tumor lysis, complementing T cell-mediated killing and targeting therapy-refractory cancers.

Purpose of the Study:

• To explore novel strategies for enhancing NK cell-based cancer immunotherapy.
• To leverage recent advances in understanding NK cell activation pathways.
• To identify new therapeutic targets for refractory cancers.

Main Methods:

• Reviewing current literature on NK cell biology and cancer immunotherapy.
• Analyzing strategies targeting NK cell inhibitory and activating receptors.
• Investigating methods to overcome tumor microenvironment-induced immunosuppression.
• Exploring the use of chimeric antigen receptors (CARs) for NK cell-directed cancer therapy.

Main Results:

• Recent advances focus on enhancing NK cell reactivity by targeting immunosuppressive tumor microenvironments.
• Modulating intracellular checkpoint molecules and incorporating CARs show promise for boosting NK cell anti-cancer activity.
• Combining NK cell-based therapies with other treatments may yield synergistic effects.

Conclusions:

• Restoring or enhancing NK cell function in the tumor microenvironment is a promising avenue for cancer treatment.
• Targeting NK cell activation pathways, including immune checkpoints and intracellular molecules, offers new therapeutic opportunities.
• A deep understanding of NK cell activation is essential for designing effective combination therapies against refractory cancers.